This 2019 review article, published in the American Journal of Hospice and Palliative Medicine, explores the potential of low-dose naltrexone (LDN) as a non-opioid treatment for chronic, nonmalignant pain syndromes. The authors discuss how LDN, administered in doses of 1 to 5 mg daily, may act as a glial modulator,
